AP Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	32.25	32.25	-
Gross Profit	32.25	32.25	-
Selling, General & Admin	57.66	43.13	34.82
Research & Development	430.48	336.6	262.68
Operating Expenses	488.15	379.73	297.5
Operating Income	-455.89	-347.48	-297.5
Interest Expense	-1.75	-1.2	-
Interest & Investment Income	8.7	10.03	2.58
Currency Exchange Gain (Loss)	1.31	-0.83	6.27
Other Non Operating Income (Expenses)	0.16	0.19	0.11
EBT Excluding Unusual Items	-447.48	-339.29	-288.54
Gain (Loss) on Sale of Assets	-0	-0	-
Pretax Income	-447.49	-339.3	-288.54
Net Income	-447.49	-339.3	-288.54
Net Income to Common	-447.49	-339.3	-288.54
Shares Outstanding (Basic)	65	65	53
Shares Outstanding (Diluted)	65	65	53
Shares Change (YoY)	7.45%	22.98%	-
EPS (Basic)	-6.87	-5.24	-5.48
EPS (Diluted)	-6.87	-5.24	-5.48
Free Cash Flow	-426.18	-332.65	-277.1
Free Cash Flow Per Share	-6.54	-5.14	-5.26
Gross Margin	100.00%	100.00%	-
Operating Margin	-1413.49%	-1077.35%	-
Profit Margin	-1387.42%	-1051.98%	-
Free Cash Flow Margin	-1321.37%	-1031.37%	-
EBITDA	-443.98	-335.88	-290.07
D&A For EBITDA	11.91	11.6	7.42
EBIT	-455.89	-347.48	-297.5

Updated Aug 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.